<SEC-DOCUMENT>0001104659-23-052046.txt : 20230428
<SEC-HEADER>0001104659-23-052046.hdr.sgml : 20230428
<ACCEPTANCE-DATETIME>20230428070425
ACCESSION NUMBER:		0001104659-23-052046
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230428
FILED AS OF DATE:		20230428
DATE AS OF CHANGE:		20230428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39997
		FILM NUMBER:		23860097

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2314078d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of  April 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39997</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adagene Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4F, Building C14, No.&nbsp;218</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Xinghu Street, Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suzhou, Jiangsu Province, 215123</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>People&#8217;s Republic of China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+86-512-8777-3632</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F
</FONT><FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; <B>&nbsp;</B>Form&nbsp;40-F <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adagene Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Peter (Peizhi) Luo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Peter (Peizhi) Luo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 28, 2023</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="tm2314078d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2314078d1_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release titled &ldquo;Adagene Announces Updates to its Board of Directors.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>






<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2314078d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2314078d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Adagene Announces Updates to its Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">SAN DIEGO and SUZHOU, China, April&nbsp;28,
2023 &ndash; </FONT>Adagene Inc. (&ldquo;Adagene&rdquo;) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming
the discovery and development of novel antibody-based therapies today announced updates to its board of directors (the &ldquo;Board&rdquo;),
including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Mervyn Turner, Ph.D.</I></B>, is appointed as a director. Dr.&nbsp;Turner
accumulated over 25 years of experience at Merck Research Laboratories in pharmaceuticals drug discovery, research and development, licensing
and business development, emerging markets analysis, and strategy development and implementation. For seven years, he was head of worldwide
licensing and external research at Merck, during a period of rapid expansion in Merck&rsquo;s partnering activities. He became Merck&rsquo;s
first Chief Strategy Officer and a member of the senior executive team in 2008, before retiring from the company in 2011. Dr.&nbsp;Turner
received his BS and Ph.D. in Chemistry from the University of Sheffield in 1970. He also completed his postdoctoral research in biochemistry
of histocompatibility at Havard University in 1974.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Fangyong (Felix) Du, Ph.D., </I></B>is appointed as a director. Dr.&nbsp;Du
joined Adagene as Vice President of Technology Development in January&nbsp;2012 and has served as Chief Technology Officer since May&nbsp;2019.
Dr.&nbsp;Du has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles in
world-renowned scientific journals such as Nature and Science. Dr.&nbsp;Du worked at Affomix from October&nbsp;2009 to July&nbsp;2010
and Illumina from July&nbsp;2010 to January&nbsp;2012, and then joined the Company in January&nbsp;2012 as the Vice President
of Technology Development. Dr.&nbsp;Du received his Ph.D. degree in biology from the California Institute of Technology in 2001 and his
bachelor&rsquo;s degree and master&rsquo;s degree in physiology and biophysics in 1991 and 1994, respectively, from Peking University.
Dr.&nbsp;Du also completed his postdoctoral research from Yale University..</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Yumeng Wang,</I></B> replaces Lefei Sun as a director immediately prior
to filing of the annual report of the Company for the year of 2022 (the &ldquo;Annual Report&rdquo;), as designated by General Atlantic
Singapore AI Pte. Ltd. pursuant to Adagene&rsquo;s current effective memorandum and articles of association. Ms.&nbsp;Wang is a vice president
at General Atlantic, primarily responsible for investments in healthcare and life sciences sectors. Prior to joining General Atlantic,
Ms.&nbsp;Wang served as an equity research analyst at The Hongkong and Shanghai Banking Corporation, mainly focusing on the healthcare
sector. Ms.&nbsp;Wang also serves as a non-executive director of Ocumension Therapeutics (1477.HK) and Biotheus Inc. Ms.&nbsp;Wang received
her bachelor&rsquo;s degree in business administration in June&nbsp;2013 and her master's degree in biotechnology in 2021 from The Hong
Kong University of Science and Technology.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">As a result of Yumeng Wang&rsquo;s replacement of Lefei Sun, he has resigned
from the Board. Additionally, Yuwen Liu has resigned from the Board and audit committee of the Board effective upon filing of the Annual
Report, due to expiration of her initial appointment as a director and an audit committee member. Adagene appreciates the service of Ms.&nbsp;Liu
and her contributions to the Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Each of Lefei Sun and Yuwen Liu has confirmed that there is no disagreement
with the Board and there is no matter relating to his or her resignation that needs to be brought to the attention of the shareholders
of the Company.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2314078d1_ex99-1img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;We are excited to welcome Drs.&nbsp;Turner
and Du and Ms.&nbsp;Wang to our Board, as we work to advance our differentiated clinical products rapidly to reach critical value inflection
points, harvest value from our preclinical assets, and fully leverage our platform technologies to drive future growth,&rdquo; said </FONT>Peter
Luo<FONT STYLE="color: #333333; background-color: white">, Ph.D., Co-Founder, Chief Executive Officer and Chairman of the Board of&nbsp;</FONT>Adagene<FONT STYLE="color: #333333; background-color: white">.</FONT>
 &ldquo;I am also appreciative of Lefei Sun&rsquo;s many contributions during his past four years of service and the contributions of Yuwen
Liu in the past year. I look forward to working with the new directors who bring a breadth of industry experience and new insights to
our Board.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Adagene</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Adagene Inc. (Nasdaq: ADAG) is a platform-driven,
clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
</FONT>Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody&trade;, SAFEbody&reg;, and POWERbody&trade; technologies,
Adagene&rsquo;s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with
reputable global partners that leverage its technology in multiple approaches at the vanguard of science.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">For more information, please visit:<U>&nbsp;</U></FONT><U>https://investor.adagene.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #333333; background-color: white">SAFEbody<SUP>&reg;</SUP>&nbsp;is
a registered trademark in&nbsp;</FONT>the United States<FONT STYLE="color: #333333; background-color: white">,&nbsp;</FONT>China<FONT STYLE="color: #333333; background-color: white">,&nbsp;</FONT>Australia<FONT STYLE="color: #333333; background-color: white">,&nbsp;</FONT>Japan<FONT STYLE="color: #333333; background-color: white">,&nbsp;</FONT>Singapore<FONT STYLE="color: #333333; background-color: white">,
and the&nbsp;</FONT>European Union<FONT STYLE="color: #333333; background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #333333; background-color: white">This
press release contains forward-looking statements, including statements regarding the potential implications of clinical data for patients,
and Adagene&rsquo;s advancement of, and anticipated clinical activities, clinical development, regulatory milestones, and commercialization
of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of
various important factors, including but not limited to Adagene&rsquo;s ability to demonstrate the safety and efficacy of its drug candidates;
the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing
of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene&rsquo;s drug candidates; Adagene&rsquo;s
ability to achieve commercial success for its drug candidates, if approved; Adagene&rsquo;s ability to obtain and maintain protection
of intellectual property for its technology and drugs; Adagene&rsquo;s reliance on third parties to conduct drug development, manufacturing
and other services; Adagene&rsquo;s limited operating history and Adagene&rsquo;s ability to obtain additional funding for operations
and to complete the development and commercialization of its drug candidates; Adagene&rsquo;s ability to enter into additional collaboration
agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene&rsquo;s clinical
development, commercial and other operations, as well as those risks more fully discussed in the &ldquo;Risk Factors&rdquo; section in
Adagene&rsquo;s filings with the&nbsp;</FONT>U.S. Securities and Exchange Commission<FONT STYLE="color: #333333; background-color: white">.
All forward-looking statements are based on information currently available to&nbsp;</FONT>Adagene<FONT STYLE="color: #333333; background-color: white">,
and&nbsp;</FONT>Adagene<FONT STYLE="color: #333333; background-color: white">&nbsp;undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor&nbsp;&amp; Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Ami Knoefler<BR>
Adagene<BR>
650-739-9952<BR>
</FONT><U>ir@adagene.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2314078d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2314078d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R -$# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^D)"@DG
M'))I:P/&NI?V5X/U.Y#8<PF-/]YOE'\\_A3BN9I$SDHQ<GT,+1/BCI^MZ[!I
M<=C/$9V*I*[#&0"1Q[X_6N\KYALTN-%DTG7,'8TYDC]_+9<_SKZ;AE2XA2:)
M@T<BAE8="#R#73B:48-<NQPX'$3JIJINOR9B>+/%$/A/38KV>VDG6281!48
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M=/.D.X#M@C%=S7-.*B]'<]O#5JE6+=2FX>MOT"BBBH.H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2314078d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2314078d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R ,@# 2(  A$! Q$!_\0
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M\9LT8I#.R G>_. ?:O8T^X/I7A_QA_Y'"W_Z\D_]#>NCD^,VGI#^YTJZ=P.
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MT,VW[OF1AL?3-2Q1I%$(XT5$4855& !["BBBX*,4[I:E0Z/IC$LVFV9).23
MO/Z4G]C:5_T#;/\ [\+_ (444^:7<S]C3_E7W+_(FM["SM)"UM:00L1@F.,*
/2/PHHHI7N:1BHJT58__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
